Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Total Non-Current Liabilities (2020 - 2025)

Candel Therapeutics' Total Non-Current Liabilities history spans 4 years, with the latest figure at $27.5 million for Q4 2023.

  • On a quarterly basis, Total Non-Current Liabilities fell 1.98% to $27.5 million in Q4 2023 year-over-year; TTM through Dec 2023 was $27.5 million, a 1.98% decrease, with the full-year FY2023 number at $27.5 million, down 1.98% from a year prior.
  • Total Non-Current Liabilities hit $27.5 million in Q4 2023 for Candel Therapeutics, up from $26.6 million in the prior quarter.
  • Over the last five years, Total Non-Current Liabilities for CADL hit a ceiling of $28.3 million in Q3 2022 and a floor of $5.5 million in Q3 2021.
  • Historically, Total Non-Current Liabilities has averaged $20.3 million across 4 years, with a median of $26.8 million in 2023.
  • Biggest five-year swings in Total Non-Current Liabilities: soared 411.57% in 2022 and later decreased 5.83% in 2023.
  • Tracing CADL's Total Non-Current Liabilities over 4 years: stood at $6.0 million in 2020, then increased by 14.5% to $6.8 million in 2021, then skyrocketed by 312.19% to $28.1 million in 2022, then fell by 1.98% to $27.5 million in 2023.
  • Business Quant data shows Total Non-Current Liabilities for CADL at $27.5 million in Q4 2023, $26.6 million in Q3 2023, and $26.9 million in Q2 2023.